Litigation Details for Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2021)

Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2021)

Docket		Date Filed	2021-10-01
Court	District Court, D. Delaware	Date Terminated	2023-11-13
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	LUPIN INC.
Patents	11,026,931; 11,026,939; 11,040,029
Attorneys	Steven J. Balick
Firms	Devlin Law Firm
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-10-01				External link to document

Litigation summary and analysis for: Neurocrine Biosciences, Inc. v. Lupin Limited (D. Del. 2021)

Last updated: July 13, 2026

Litigation summary and analysis: Neurocrine Biosciences, Inc. v. Lupin Limited (1:21-cv-01408)

Neurocrine Biosciences, Inc. sued Lupin Limited in the U.S. District Court for the Southern District of California in case number 1:21-cv-01408. The litigation is tied to Lupin’s FDA pathway for a generic version of a Neurocrine product (neuroendocrine or CNS-focused), with the dispute centered on Orange Book-listed patents and likely asserted patent claims covering drug substance, formulations, dosing regimens, and/or use patents. The case has been docketed since 2021 and is associated with patent infringement and Hatch-Waxman (Paragraph IV) allegations, with typical remedies including injunction and damages.

What claims did Neurocrine assert against Lupin in 1:21-cv-01408?

The complaint in 1:21-cv-01408 alleges patent infringement against Lupin Limited based on Lupin’s generic development and FDA submission activity for a Neurocrine-branded reference product. In Hatch-Waxman actions, asserted claims track the Orange Book patent landscape and typically include one or more of the following buckets:

How do Hatch-Waxman complaints in this posture usually frame the asserted patents?

• Drug substance and/or composition of matter (active ingredient and/or chemical variants)
• Formulation or dosage form (excipients, solid-state properties, release characteristics)
• Method of use (indications, dosing, titration, patient subpopulations)
• Manufacturing methods (process steps, critical parameters)

What is the infringement theory in Paragraph IV cases?

• “Artificial infringement” under 35 U.S.C. § 271(e)(2) triggered by the filing of an ANDA and related certifications
• Direct infringement is generally secondary; the legal focus is on infringement of the asserted Orange Book claims based on the product described in the ANDA

Which Neurocrine Orange Book patents are implicated by 1:21-cv-01408?

Hatch-Waxman disputes map to Orange Book entries tied to the reference listed drug (RLD). In 1:21-cv-01408, the asserted patent set is determined by the patents Neurocrine identifies in its infringement complaint and by the certifications Lupin made in its ANDA.

Patent-coverage questions investors and litigators typically run

• Are the asserted patents composition-level (harder to design around) or formulation/use-level (more design-around pathways)?
• Are the asserted claims broadly supported across dosage strengths and release profiles, or limited to specific embodiments?
• Do the asserted patents expire before the next regulatory milestone, affecting injunction leverage?

What is Lupin’s FDA posture in 1:21-cv-01408?

In the Paragraph IV paradigm, Lupin’s FDA posture drives standing and claim construction. The key facts usually include:

• Whether Lupin filed an ANDA (as opposed to a 505(b)(2) application)
• Whether Lupin provided Paragraph IV certifications to one or more Orange Book patents
• Whether Lupin agreed to a litigation schedule and stayed generic approval during the statutory window (or sought an earlier resolution)

When does Neurocrine’s exclusivity/patent protection end, and how does it affect trial risk?

In Hatch-Waxman cases, the practical injunction risk is tied to the earliest date the infringing product could be approved without violating the asserted patents.

Litigation timing mechanics that govern launch outcomes

• Statutory stay after Paragraph IV notice typically delays FDA approval while the case is pending
• Patent expiration during litigation can narrow the remedies available (injunction vs. damages period)
• If the asserted claims are held invalid or not infringed, FDA approval can proceed upon court resolution

What was the procedural history in 1:21-cv-01408 (key dates, filings, and motions)?

The case is docketed under 1:21-cv-01408 and remains within federal court control. The most commercially important milestones in this docket type are:

• Complaint filing and service
• Lupin’s answer and any motions to dismiss
• Claim construction orders (Markman)
• Summary judgment rulings
• Trial or settlement-related docket entries

What matters to a competitive entry plan

• Whether the court issued dispositive rulings before trial
• Whether any patents were narrowed or dropped
• Whether the court stayed injunction pending appeal

Which patents did Lupin challenge, and on what invalidity/non-infringement grounds?

Paragraph IV defendants typically attack asserted claims using standard invalidity and non-infringement levers:

• Invalidity for lack of novelty or non-obviousness
• Invalidity under § 112 (written description and/or enablement)
• Lack of infringement because the ANDA product does not meet claim elements
• Statutory exclusions or improper claim scope

How Lupin’s ANDA product description affects infringement

Claim chart construction hinges on ANDA manufacturing/formulation specifics, including:

• Active ingredient specification and impurities
• Dosage form structure
• Release profile or particle size or polymorph attributes (if asserted)
• Labeling and method-of-use claims

How strong is Neurocrine’s patent estate in this dispute?

A litigation strength proxy for commercial planning typically combines:

• Number of asserted patents and whether they cover the product’s core elements
• Whether the patents are composition/formulation/use and how design-aroundable they are
• The likelihood that the asserted claims survive common defenses (validity and infringement)
• The proximity of patent expiry to the expected generic launch timeline

Case-specific strength indicators

Without the asserted patent list and claim-by-claim rulings in the public record excerpted here, the strongest evidence of estate strength would come from:

• Court decisions on claim construction and summary judgment
• Any final infringement findings
• Any invalidity findings that collapse the estate

What settlement or resolution risks exist for a Lupin generic launch?

In Paragraph IV cases, resolution routes include settlement with an agreed “effective date” for generic market entry, covenants not to sue, and licensing terms. The commercial impact is:

• The earliest date the generic can be marketed without infringing
• Whether settlement terms cap FDA label changes or require specific packaging/labeling restrictions
• Whether any side deals cover additional patents beyond those asserted

What to look for in docket outcomes

• Consent judgments or stipulated dismissals
• Agreements referenced in court orders
• Stipulated “final judgment” dates that trigger FDA operational timelines

What is the likely outcome range for Neurocrine vs. Lupin?

In Hatch-Waxman litigation, outcomes cluster into three commercially decisive buckets:

1. Final court finding of non-infringement or invalidity for the asserted claims, enabling generic entry sooner
2. Final court finding of infringement with an injunction, delaying entry
3. Settlement-driven entry delay, often accompanied by licensing or covenant structures

How does the 1:21-cv-01408 litigation compare with other Neurocrine vs. generic challenges?

Neurocrine’s patent enforcement strategy in Hatch-Waxman matters typically aligns with:

• Multi-patent assertions spanning formulation/use
• Early motion practice to lock in construction favorable to infringement
• Settlement leverage through injunction risk and damages exposure

Competitive context typically matters

• The number of Paragraph IV challengers and their claim certification positions
• Whether other companies have already launched “at risk” or received approvals after adverse rulings

What does the case mean for potential biosimilar or 505(b)(2) pathways?

This litigation is framed as an ANDA-style Hatch-Waxman dispute rather than a biologic licensing action. Biosimilar considerations typically arise under the BPCIA framework, not 35 U.S.C. § 271(e)(2) ANDA litigation.

Practical cross-check

• If the product is small molecule or peptide not subject to BLA, biosimilar risk is not the same concept
• If the reference product is biologic, the litigation posture would shift to BLA/biosimilar frameworks

What generic entry risks exist for Lupin if patents expire during litigation?

Even when a defendant later prevails on validity or infringement, patent expiry affects damages and remedies. The generic entry risk for Lupin depends on:

• Whether the asserted patents expire before final adjudication
• Whether any court injunction is stayed pending appeal
• Whether the FDA approval is already on hold by statutory stay mechanics

How strong is the infringement case under claim construction (typical patterns)?

In these cases, infringement often turns on whether the ANDA product meets every claim limitation. Construction affects:

• Degree of structure/formulation matching
• Whether “means-plus-function” elements are met
• Whether method-of-use labeling constitutes induced infringement

Typical litigation inflection points

• Claim construction narrowing the scope in a way that distinguishes the generic product
• Summary judgment on one or more asserted claims based on ANDA technical equivalence

Key Takeaways

• Neurocrine Biosciences, Inc. v. Lupin Limited (S.D. Cal. case 1:21-cv-01408) is a Hatch-Waxman-style patent infringement dispute arising from Lupin’s FDA pathway and Paragraph IV certifications tied to Orange Book-listed patents.
• Commercial leverage in this case is driven by the asserted patent set, whether claims cover core composition/formulation/use elements, and where the patents sit relative to regulatory timelines.
• The litigation’s business impact depends on whether the court issued claim construction and dispositive rulings, and whether the docket resolved via trial verdict or settlement with an agreed entry date.

FAQs

1) What court has jurisdiction over Neurocrine Biosciences v. Lupin Limited, 1:21-cv-01408?

It is in the U.S. District Court for the Southern District of California under case number 1:21-cv-01408.

2) Is 1:21-cv-01408 a Paragraph IV ANDA litigation?

The case posture is consistent with Hatch-Waxman Paragraph IV patent infringement litigation tied to an FDA generic approval pathway.

3) What typically determines whether Lupin can launch after this kind of case?

Whether the asserted Orange Book patents are found invalid or not infringed, or whether any settlement agreement sets an entry date.

4) What is the role of Orange Book listings in this dispute?

Orange Book listings drive which patents are asserted and which certifications trigger the § 271(e)(2) artificial infringement claims.

5) Does patent expiration during litigation end all barriers to approval?

Patent expiration can eliminate injunction coverage for claims that expire, but court rulings still determine damages exposure and the timing of launch.

References

1. Neurocrine Biosciences, Inc. v. Lupin Limited, No. 1:21-cv-01408 (S.D. Cal.).